London Daily

Focus on the big picture.
Tuesday, Jul 22, 2025

Chinese researchers find third Sinovac dose boosts Delta immune response

Chinese researchers find third Sinovac dose boosts Delta immune response

A number of countries are considering boosters or authorising them for certain groups amid the battle against the Delta variant.

A third dose of the Covid-19 vaccine by Sinovac Biotech can boost a flagging immune response to the highly transmissible Delta variant, a team of Chinese researchers has found.

Study participants who received a three-dose regimen of the Sinovac shot showed a more than 2½ times higher neutralising ability against Delta four weeks after the last shot, compared with those who received two doses or had recovered from a naturally acquired Covid-19 infection, according to the small-scale study that has not been peer-reviewed.

The researchers – including scientists from the Chinese Academy of Sciences, Peking University and the vaccine maker – said their data also indicated a third dose would allow vaccine protection to last longer.


The findings “rationalise the use of three-dose immunisation regimens for inactivated vaccines”, they wrote in a paper released on the server medRvix on Sunday.

“Our results demonstrate that a third-dose booster of inactivated vaccine can elicit an expeditious, robust and long-lasting recall humoral [immune] response,” they wrote.

Chinese health officials late last month recommended booster shots for high-risk and vulnerable groups, but said further study was needed before extra jabs were considered for the general public. Five of the seven vaccines in use domestically use an inactivated platform, which relies on a dead version of the virus to stimulate immune response.

Sinovac’s Covid-19 vaccine is among products headlining the domestic roll-out, which has surpassed 2 billion doses. The two-dose vaccine is also widely used around the world.

Limited real-world data has been published on how well the vaccine defends against the Delta variant, which is expected to become dominant worldwide.

Several countries are offering third shots of other vaccines as a boost to Sinovac’s shots following concerns about breakthrough infections as Delta spreads.

But vaccine makers globally have reported diminished protection against the strain, especially against symptomatic disease. A number of countries are considering boosters, or authorising them for certain groups, as concerns loom about the longevity of vaccines and a reduced ability to counter the Delta variant.

The latest study of Sinovac, which relied on lab work not real-world evidence, indicated that four weeks after their final dose the neutralising antibody levels evoked against the Delta variant in people vaccinated with two shots of Sinovac’s vaccine were reduced about 3.7 times compared to that against the original strain.

The researchers also found that six months after vaccination, people who received two doses did not have detectable neutralising activity against the Beta, Gamma and Delta variants, but after the third dose they “exhibited a robust recall” immune response to neutralise variants.

They said their research showed neutralising antibody levels similar to those recorded soon after the second dose were maintained 180 days after the third-dose booster – suggesting the vaccine could last longer with an additional shot.

The study included 22 people who had recovered from Covid-19, six healthy participants and 38 volunteers who received either two or three doses of the vaccine.


The researchers did not discuss what level of protection the vaccine would have against the Delta variant in the real world or the effectiveness against Delta for those six months out from their full vaccination.

Neutralising antibodies are believed to be a key component of the body’s immune defence and an indicator of vaccine effectiveness, but levels typically decline over time.

Another laboratory-based study by a team of British and Indian researchers released on Tuesday found Delta was six times less sensitive to antibodies from individuals who had recovered from a previous infection compared with the earlier dominant strain of the virus.

The variant was also eight times less sensitive to antibodies produced by vaccination with either the Pfizer-BioNTech or AstraZeneca vaccines. The researchers said there was a need to explore “strategies to boost vaccine responses”.

Newsletter

Related Articles

0:00
0:00
Close
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
×